To be driven by Eurohealth Systems, the partnership will enable Aster DM Healthcare facilities across UAE, KSA, Qatar and Oman to adopt advanced diagnostic innovations and solutions from Roche Diagnostics to introduce smart systems.
The Aster laboratory consolidation project will use Roche’s expertise to transform Aster’s existing systems into a single platform with the latest state-of-art technology, aimed at providing optimal results to patients and their treating physicians.
Dubai, United Arab Emirates, 31 May 2021: Aster DM Healthcare, the largest integrated healthcare provider in the Middle East, today signed a Memorandum of Understanding (MoU) with Roche Diagnostics, the world leader in biotechnology, as the strategic partner across the United Arab Emirates (UAE), the Kingdom of Saudi Arabia (KSA), Qatar and Oman.
The partnership between these two leading healthcare companies, will enable Aster DM Healthcare’s hospitals, clinics and laboratories across the region to adopt the latest diagnostic innovations and solutions that would bring-in fast and efficient systems to support doctors in providing optimal treatment solutions to their patients. . This also includes the provision of antibody COVID-19 testing, digital solutions, as well as automated laboratory solutions that will further enable Aster facilities to deliver high-quality and precise patient results in the shortest time possible, while boosting capabilities to drive operational efficiency essential to meet the rising demand for diagnostics in this pandemic and beyond.
Alisha Moopen, Deputy Managing Director at Aster DM Healthcare, said, “At Aster, we are determined to stay ahead of the curve in offering the best medical solutions to our patients and equip our doctors with the most advanced systems to be able to do so. The partnership with Roche Diagnostics in the Middle East underscores our dedication to supporting countries, patients and medical fraternity across the region through providing the latest healthcare solutions relating to the prevention, diagnosis and treatment of various diseases. This is a part of our core strategy to introduce smart systems that encourages early and accurate detection that can facilitate timely medical intervention essential to prevent unwanted disease outcomes.”
Also in attendance was Stavros Chisimellis, Head of Gulf region, Agencies business & Distribution at Roche Diagnostics Middle East, who stated, “At Roche Diagnostics, we put patient-care at the heart of all our endeavors. Through this collaboration with Aster DM Healthcare, we aim to accelerate the process of providing the highest quality healthcare and the latest diagnostic solutions to all citizens and residents here in the UAE and across the Middle East.”
Commenting on the project, Hanie Abdul Sathar, Director at Eurohealth Systems said, “This project marks the start of a transformation journey that would enhance the service offering of Aster Laboratories across GCC, while through system integration and consolidation we are aiming to develop state-of-art infrastructure for diagnostics founded on intelligent systems, sophisticated quality procedures, instrument technology enhancements, all with the purpose of equipping our doctors with the best systems needed to be able to provide the optimal treatment solution to patients.”
The Aster laboratory consolidation project is aimed at integrating future-ready systems within the company’s expansive network of 13 hospitals, 106 clinics and laboratories in the GCC. Aimed at driving precision in diagnostics with speed and operational efficiency, the project will further strengthen the company’s ability to identify and immediately serve patient needs.
Through the use of Roche’s latest diagnostic solutions Aster DM Healthcare’s facilities will be able to enhance capacity to test for multiple diseases by taking minimal samples from patients. This will especially be of help for more vulnerable patients such as the elderly, children, and those living with conditions such as hemophilia or other blood diseases where taking a blood sample is cumbersome and could potentially be dangerous.
Furthermore, the partnership will allow both Aster Hospitals and Roche to continue fulfilling its commitment towards the prevention, diagnosis, and treatment of various disease areas, including cardiovascular health, women’s health, infectious diseases. In doing so, the companies aim to support the welfare of the regional community and provide patients across the Middle East with world-class healthcare.
Aster DM Healthcare Limited is one of the largest integrated healthcare service providers operating in GCC and an emerging healthcare player in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare through our 27 hospitals, 115 clinics and 225 pharmacies. We have over 21,000 plus dedicated employees including 2887 doctors and 6283 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: “We’ll treat you well.” We cater to all economic segments of the society through our three brands: Aster, Access and Medcare. For more information, please visit
RDME has taken the unprecedented step of being the first IVD Company to have a Management Centre in the Middle East. RDME has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region through the appropriate channels. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services through the appropriate channels. With this regional empowerment, RDME has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.
RDME offers comprehensive expertise through the relevant and appropriate channels in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives. For more information, please visit
Head of Corporate Communications
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
MOHAP License: I7YLGUJ8-160822